Action Resverlogix - RVX

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,04

Prix Achat

0,035

Prix Vente

0,04

Volume échangé

0,00 Fourchette du Jour 0,00

0,035 Plage de 52 semaines 0,095

Cap du marché

11,261M

Clôture Veille

0,04

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

43 461

Actions en circulation

281 537 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,48

Bénéfice par action (BPA)

-0,03

Chiffre d'affairess

50k

Bénéfice net

-7,64M

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.resverlogix.com

Siège social

Calgary, Alberta, Can

Fondé

Resverlogix Corp est coté dans le secteur Biological Pds,ex Diagnstics de la Toronto Stock Exchange avec le ticker RVX. Le dernier cours de clôture d'Resverlogix était de $0,04. Au cours de la dernière année, les actions de Resverlogix ont été négociées dans une fourchette de prix de $ 0,035 à $ 0,095.

Resverlogix compte actuellement 281 537 000 actions en circulation. La capitalisation boursière d'Resverlogix est de $11,26 million. Resverlogix a un ratio cours/bénéfice (ratio PE) de -1.48.

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.04	0.04	0.035	92251	0.0399458	CS
4	0	0	0.04	0.05	0.035	53803	0.04238836	CS
12	-0.015	-27.2727272727	0.055	0.055	0.035	43461	0.04551606	CS
26	-0.025	-38.4615384615	0.065	0.065	0.035	51493	0.05258242	CS
52	-0.02	-33.3333333333	0.06	0.095	0.035	59646	0.06166762	CS
156	-0.4	-90.9090909091	0.44	0.44	0.035	65950	0.12298442	CS
260	-0.85	-95.5056179775	0.89	1.52	0.035	62958	0.36749028	CS

RVX - Frequently Asked Questions (FAQ)

What is the current Resverlogix share price?

The current share price of Resverlogix is $ 0,04

How many Resverlogix shares are in issue?

Resverlogix has 281 537 000 shares in issue

What is the market cap of Resverlogix?

The market capitalisation of Resverlogix is CAD 11,26M

What is the 1 year trading range for Resverlogix share price?

Resverlogix has traded in the range of $ 0,035 to $ 0,095 during the past year

What is the PE ratio of Resverlogix?

The price to earnings ratio of Resverlogix is -1,48

What is the cash to sales ratio of Resverlogix?

The cash to sales ratio of Resverlogix is 200

What is the reporting currency for Resverlogix?

Resverlogix reports financial results in USD

What is the latest annual turnover for Resverlogix?

The latest annual turnover of Resverlogix is USD 50k

What is the latest annual profit for Resverlogix?

The latest annual profit of Resverlogix is USD -7,64M

What is the registered address of Resverlogix?

The registered address for Resverlogix is 4820 RICHARD ROAD S.W, SUITE 300, CALGARY, ALBERTA, T3E 6L1

What is the Resverlogix website address?

The website address for Resverlogix is www.resverlogix.com

Which industry sector does Resverlogix operate in?

Resverlogix operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
134AUPraise Inc	0,00 (0,00%)	0
1332Nissui Corporation	0,00 (0,00%)	0
132AIN Holdings Co Ltd	0,00 (0,00%)	0
131ACCN Group Corp	0,00 (0,00%)	0
130AVeritas In Silico Inc	0,00 (0,00%)	0
134AUPraise Inc	0,00 (0,00%)	0
1332Nissui Corporation	0,00 (0,00%)	0
132AIN Holdings Co Ltd	0,00 (0,00%)	0
131ACCN Group Corp	0,00 (0,00%)	0
130AVeritas In Silico Inc	0,00 (0,00%)	0
134AUPraise Inc	0,00 (0,00%)	0
1332Nissui Corporation	0,00 (0,00%)	0
132AIN Holdings Co Ltd	0,00 (0,00%)	0
131ACCN Group Corp	0,00 (0,00%)	0
130AVeritas In Silico Inc	0,00 (0,00%)	0

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Resverlogix Corp (RVX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Resverlogix Corp

RVX Dernières nouvelles

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

RVX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Resverlogix Corp (RVX) Cours

Resverlogix Corp (RVX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Resverlogix Corp

RVX Dernières nouvelles

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

RVX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Supprimer les publicités